论文部分内容阅读
目的结肠癌患者在围手术期因疾病原因多出现贫血症状,临床治疗方法相对有限,重组人促红细胞生成素(rh-EPO)疗效较好被临床广泛应用,但近来不良反应报道不断,如何更好的解决结肠癌围手术期贫血问题显得越发突出。方法观察rh-EPO组与rh-EPO联合生血片组治疗结肠癌不同Dukes分期的患者,并观察术前1周和术后2周Hb、RBC、HCT变化情况。结果术后2周DukesC和D期Hb数值,rh-EPO联合生血片组分别为(126.8±15.2)g/L、(120.8±15.8)g/L优于rh-EPO组的(109.6±9.6)g/L、(101.3±9.6)g/L(P≤0.05)。结论 rh-EPO联合生血片具有增效减毒的作用,特别是对DukesC、D期病情复杂的结肠癌患者临床意义更加明显。
The purpose of colon cancer patients in the perioperative period due to disease causes more anemia symptoms, clinical treatment is relatively limited, recombinant human erythropoietin (rh-EPO) better effect is widely used clinically, but recently reported adverse reactions, how to more A good solution to the problem of perioperative colon cancer is more prominent. Methods The patients with different Dukes stage of colon cancer were treated with rh-EPO and rh-EPO in combination with Shengxue Tablet. The changes of Hb, RBC and HCT at 1 week and 2 weeks after operation were observed. Results The Hb values of DukesC and D in two weeks after operation were (126.8 ± 15.2) g / L and (120.8 ± 15.8) g / L, respectively, higher than those in rh-EPO group (109.6 ± 9.6) g / L, (101.3 ± 9.6) g / L (P≤0.05). Conclusions rh-EPO combined with Shengxue Tablet has synergistic effect and attenuation effect, especially for patients with complicated colon cancer in DukesC, D stage, the clinical significance is more obvious.